Asset
Mivocabtagene Autoleucel
Kyverna Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06400303 | phase1_2 | terminated | 2024-08-06 | 2026-06-16 | Kyverna Therapeutics | KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis |
| NCT06193889 | phase2_3 | recruiting | 2024-08-28 | 2027-09-01 | Kyverna Therapeutics | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis |
| NCT06384976 | phase2 | active_not_recruiting | 2024-09-20 | 2027-04-01 | Kyverna Therapeutics | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis |
FDA applications (0)
This company has no applications containing this asset.